AI Summary
We reviewed 418 live results for hulio (adalimumab) distribution and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Pharmaceutical Distribution and Healthcare Services.
Comparison Table
Source: Viatris (Thailand) Limited
Description
Distribution and medical information services for the Adalimumab biosimilar, Hulio. While the portfolio transitioned to Biocon Biologics, Viatris remains a key historical reference and provider associated with the medication's entry into the Thailand market.
Best for
hospital pharmacy sourcing, specialty medication access and healthcare provider inquiries
Rating
Source: Viatris / Fujifilm Kyowa Kirin Biologics
Description
Hulio is an adalimumab biosimilar listed in Singapore's National Drug Formulary. It is available in 40mg/0.8ml pre-filled pens and syringes for treating inflammatory conditions such as rheumatoid arthritis and psoriasis.
Best for
immune-mediated disorders, Singapore NDF access and subcutaneous administration
Rating
Source: Biocon Biologics Ltd
Description
Hulio (adalimumab-fkjp) is a prescription biologic medication and FDA-approved biosimilar to Humira. It is a tumor necrosis factor (TNF) blocker used to treat various inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. The medication is available as a citrate-free subcutaneous injection in both a 40 mg/0.8 mL pre-filled autoinjector pen and a pre-filled syringe format. As an interchangeable biosimilar, it offers a clinical alternative for patients managing autoimmune and chronic inflammatory disorders.
Best for
rheumatoid arthritis patients, inflammatory bowel disease management, cost-conscious biologic users, psoriasis treatment and subcutaneous injection therapy
Rating
| Compare | Hulio (Adalimumab) Distribution | Hulio | Hulio (adalimumab-fkjp) |
|---|---|---|---|
| Source | Viatris (Thailand) Limited | Viatris / Fujifilm Kyowa Kirin Biologics | Biocon Biologics Ltd |
| Description | Distribution and medical information services for the Adalimumab biosimilar, Hulio. While the portfolio transitioned to Biocon Biologics, Viatris remains a key historical reference and provider associated with the medication's entry into the Thailand market. | Hulio is an adalimumab biosimilar listed in Singapore's National Drug Formulary. It is available in 40mg/0.8ml pre-filled pens and syringes for treating inflammatory conditions such as rheumatoid arthritis and psoriasis. | Hulio (adalimumab-fkjp) is a prescription biologic medication and FDA-approved biosimilar to Humira. It is a tumor necrosis factor (TNF) blocker used to treat various inflammatory conditions, including rheumatoid arthritis, Crohn's disease, and plaque psoriasis. The medication is available as a citrate-free subcutaneous injection in both a 40 mg/0.8 mL pre-filled autoinjector pen and a pre-filled syringe format. As an interchangeable biosimilar, it offers a clinical alternative for patients managing autoimmune and chronic inflammatory disorders. |
| Best for | hospital pharmacy sourcing, specialty medication access and healthcare provider inquiries | immune-mediated disorders, Singapore NDF access and subcutaneous administration | rheumatoid arthritis patients, inflammatory bowel disease management, cost-conscious biologic users, psoriasis treatment and subcutaneous injection therapy |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Hulio (Adalimumab) Distribution from Viatris (Thailand) Limited."
I picked this because Viatris provides established medical expertise and a broad distribution network for specialty pharmaceuticals in Thailand.
Share this search
Related Finds